Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report

• Egile Nagusiak: Massine Fellouah (Egilea), Marie-Hélène Auclair (Egilea), Suzanne Fortin (Egilea), Jérémie Berdugo (Egilea), Lara de Guerké (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Pembrolizumab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1). It is used in the management and treatment of various oncologic conditions. To name a few: refractory and advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcin...